New combo therapy shows promise for AML patients without FLT3 mutation
Disease control
Completed
This study tested whether adding the drug quizartinib to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) that does not have a FLT3 mutation. About 273 patients received either quizartinib or a placebo alongside their regular chemo. The main go…
Phase: PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated May 11, 2026 20:40 UTC